RRM1 and lung carcinoma: A prospective randomized phase III trial by Reynolds et al (2009) [11] failed to demonstrate substantial difference in survival according to RRM1 levels in lung cancer patients treated with gemcitabine and carboplatin or gemcitabine monotherapy.